In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma

Keller Lab

Mechanism-based Cancer Therapies


Our utmost goal is to identify and target crucial cancer cell vulnerabilities while sparing normal tissue. From discovery approaches to validation and preclinical testing. Aiming for clinical application.

Cancer originates from normal cells through genetic and epigenetic alterations. By employing forward genomic screening we start from a known gene mutation or cancer-associated condition and investigate the path that results in a manifest malignancy. Major further focus areas of the lab include: oncoprotein-induced disturbance of post-translational protein modifications, in particular SUMOylation, and sensing of DNA damage; constitutively activated B-cell receptor and chemokine receptor signaling; and molecular cancer imaging and theranostics.


Group Leader

Prof. Dr. med. Ulrich Keller


Markus Schick, M.Sc., Postdoc

Matthias Wirth, PD Dr. rer. nat., Scientist

Stefan Habringer, Dr. med. Dr. univ., Clinician scientist

Jolanta Slawska, M.Sc.,  Technical assistant (affiliation: TUM)

Konstandina Isaakidis, B.Sc., Technical assistant

Veronika Schulze, M.Sc., Technical assistant

Stefanos Alexandros Bamopoulos, Clinician scientist

Nikita Nikita, PhD student

Le Zhang, MD student

Minh Ho, B.Sc., Technical assistant

Yingfen Hong, MD student (TUM)

Josefina Doffo, M.Sc., PhD student (affiliation: TUM)

Elena Rohleder, Dr. med., Clinician scientist

Sven Liebig, Clinician scientist 

Francis Baumgartner, Dr. med., Clinician scientist 

Uta Demel, Dr. med., Clinician scientist

Richard Lewis, MD student (affiliation: TUM/Charité)

Stavroula Litsiou, Pharmacist, PhD student

Laura Schmalbrock, Dr. med., Clinician scientist

Enio Gjerga,, Bioinformatician, Postdoc


Currently, the Keller Group focuses on the following research projects:

Myc-associated cancer biology


Functional genomic screening


Aberrant Ub/SUMO activity in cancer


Chemokine receptor signaling


Functional imaging and theranostics




  • Deutsche Forschungsgemeinschaft (SFB 824, SFB 1335)
  • Deutsche Krebshilfe
  • Sander Stiftung
  • EU/BMBF Horizon 2020
  • German Cancer Consortium (DKTK)
  • Stiftung Charité
  • Berlin Institute of Health (BIH)
  • Berliner Krebsgesellschaft